Not available
Quote | Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Last: | $27.25 |
---|---|
Change Percent: | 0.75% |
Open: | $26.36 |
Close: | $27.25 |
High: | $27.2753 |
Low: | $26.03 |
Volume: | 489,611 |
Last Trade Date Time: | 03/27/2024 03:00:00 am |
News | Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
2024-03-26 16:07:33 ET More on Rocket Pharmaceuticals Rocket Pharmaceuticals' Promising Path In Gene Therapy Rocket Pharmaceuticals GAAP EPS of -$0.64 beats by $0.14 FDA extends review period for Rocket gene therapy to June 30 Seeking Alpha’s Quant Rat...
Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planning, commercial finance, and capital allocation Additional key appointments within existing corporate leadership team expand capabilities and expertise spanning ea...
Message Board Posts | Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $RCKT News Article - Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Hea | whytestocks | investorshangout | 03/01/2023 9:05:48 PM |
whytestocks: $RCKT News Article - Rocket Pharmaceuticals Presents Positive Clinical Data from Fancon | whytestocks | investorshangout | 12/12/2022 4:10:48 PM |
whytestocks: $RCKT News Article - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, RCKT, | whytestocks | investorshangout | 10/28/2022 7:50:57 PM |
whytestocks: $RCKT News Article - Rocket Pharmaceuticals Announces Presentations Highlighting Lentiv | whytestocks | investorshangout | 10/12/2022 3:45:49 PM |
whytestocks: $RCKT News Article - Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting | whytestocks | investorshangout | 10/10/2022 12:25:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planning, commercial finance, and capital allocation Additional key appointments within existing corporate leadership team expand capabilities and expertise spanning ea...
Advancing leading pipeline of six disclosed programs across AAV cardiovascular and LV hematology portfolios; all milestones remain on track for 2024 Expanding commercial capabilities to support launch of LV portfolio beginning with KRESLADI ™ (marnetegragene autotemcel) for...
SUIC Worldwide Holdings Ltd (SUIC) is expected to report for Q4 2023 QuantaSing Group Limited (QSG) is expected to report $0.11 for Q2 2024 uniQure N.V. (QURE) is expected to report $-1.54 for Q4 2023 Albany International Corporation (AIN) is expected to report $0.84 for Q4 2023 I...